[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute of Cancerología\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,70,100,125,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100559174","cervical-boost-by-ablative-stereotactic-radiotherapy-sabr-vs-brachytherapy-in-patients-with-cervical-carcinoma-100559174",false,"NCT06560697","Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma","Randomized Phase II Study to Measure the Safety and Efficacy of Concomitant CT\u002FRT Followed by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma in Clinical Stage IB3-IIIC1 at INCAN","SABRVICAL","Inclusion Criteria:\n\n1. People with cervical cancer \\>18 years of age.\n2. Signed informed consent form approved by the regulatory committees of both institutes and, obtained before each procedure related to the protocol, and that is not considered part of the normal care of the patient.\n3. Able to comply with scheduled visits, treatment schedules, laboratory and imaging studies, and completing quality of life questionnaires.\n4. Histological confirmation of CaCu and staged as IB3-IIIC1.\n5. Squamous cell, adenosquamous, or adenocarcinoma histology.\n6. No prior treatment for cervical cancer.\n7. With disease measurable by CT, MRI, or PET\u002FCT according to REC 1.1 criteria. This measurement must be carried out 28 days before randomization.\n8. Functional status of 0-2 according to WHO criteria.\n9. Charlson Comorbidity Index of 1-4\n10. Candidates to receive cisplatin.\n11. Normal hematological, kidney, and hepatic function according to:\n\n    Hematological:\n\n    Hemoglobin equal to or \\>10g\u002FL. (With the possibility of transfusion prior to treatment to reach this hemoglobin level).\n\n    Leukocytes \\>4000\u002Fmm3. Platelets\\>100,000mm3. Neutrophils \\>1500 \u002F μL\n\n    Hepatic:\n\n    Total bilirubin \\\u003C1.5 X times the normal value. Transaminases \\\u003C1.5 X times the normal value.\n\n    Renal:\n\n    Creatinine \\\u003C1.3mg\u002Fdl or creatinine clearance \\> 40 mL\u002Fminute (using the Cockcroft\u002FGault formula).\n\n    Women: DepCr = (140 - Age in years) x Weight in kg x 0.85\n\n    \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ 72 x Serum Creatinine in mg\u002FdL Men: DepCr = (140 - Age in years) x Weight in kg x 1.00\n\n    \\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_ 72 x Serum Creatinine in mg\u002FdL\n12. Chest tomography without metastatic disease or infectious diseases.\n13. Negative pregnancy test in women of childbearing age.\n14. Not a candidate for another clinical trial within the institution.\n\nExclusion Criteria:\n\n1. Patients with small-cell carcinoma or other rare histologies (glassy cell carcinoma, melanoma, sarcomas, lymphomas)\n2. Patients with non-measurable disease.\n3. Patients in whom pregnancy is confirmed during the recruitment procedure.\n4. Clinical stages IIIC2-IVB.\n5. Serious infections or diseases that can be reactivated with the use of chemotherapy or that could limit its use (hepatitis or HIV).\n6. Pre-existing neuropathy of any etiology.\n7. Concomitant treatment with another experimental drug.\n8. Mental illnesses: With the intention of maximizing adherence to the study, those patients who are at risk of imminent physical aggression (evident during the interview), have intellectual disabilities or autism, and who come for consultation due to coercion will not be included in the study. their accompanying Severe major depressive disorder, with or without psychotic symptoms; patients in whom a psychiatric diagnosis coexists in addition to the abuse of some recreational substance, eating disorders, schizophrenia, or Bipolar-type Schizoaffective Disorder.\n9. Grade 3 obesity with body mass index \\>40kg\u002Fm2 according to the World Health Organization: Patients treated with pelvic radiotherapy and a body mass index \\>40kg\u002Fm2 are associated with a decrease in quality of life due to sexual, intestinal, genitourinary alterations, as well as greater toxicity due to oncological treatments offered such as intracavitary brachyter in which the positioning of the equipment in the vaginal area is significantly difficult in sedated patients. Patients with grade III obesity will not be included.\n10. Any patient who is absent from follow-up for 5 subsequent appointments will be excluded from the study.\n11. History of total or partial hysterectomy.\n12. Patients with a history of neoadjuvant chemotherapy or use of another antineoplastic drug differ from cisplatin (40 mg\u002Fm2).\n13. History of use of Bevacizumab to manage a pathology other than CC or intention to use this drug as part of the treatment of CC.\n\n15\\. Charlson Comorbidity Index \\>5 16. Synchronous Cancer except non-melanoma Skin Cancer. 17. History of pelvic irradiation for metachronous cancer. 18. Inflammatory bowel disease or collagen diseases. 19. Patients with severe immunosuppression (transplant or treatment with immunosuppressive drugs).\n\n20\\. Patients who do not sign the informed consent form. 21. Suspected alcohol or recreational drug abuse. 22. Participation in any other clinical trial in the last 90 days prior to protocol recruitment.\n\n23\\. Any illness or disability not covered by the exclusion criteria that, in the researchers' opinion, may put the patient's safety and compliance with the protocol at risk.\n\n24\\. Patients with a percentage of rectal circumference receiving a dose of 15Gy \\>62.7%","FEMALE","18 Years",{"count":20,"type":21},84,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT\u002FRT, followed by additional boosting with brachytherapy (BT). There is an international decrease in the use of this technique due to financial restrictions. Given the difficulties in using brachytherapy as a boost, several series have described promising results in local control using boost with highly conformal techniques such as stereotactic body radiotherapy (SBRT). On the other hand, prospective studies are scarce and with controversial results. No study has been published that directly compares three-dimensional intracavitary SBRT and BT. In this clinical trial, the researchers aim to demonstrate that boosting with SBRT is not inferior to intracavitary brachytherapy in patients with CC.\n\nMethodology\n\nPrimary Objective:\n\nTo evaluate the safety and efficacy of concomitant CT\u002FRT followed by Ablative Body Stereotactic Radiotherapy (SBRT) vs Brachytherapy in patients with Cervical Cancer in clinical stage IB3-IIIC1 at INCan.\n\nSecondary Objectives:\n\nThe purpose of this study is to evaluate quality of life, local efficacy (local control and time to local recurrence), overall survival, disease-free survival, and time to distant recurrence.\n\nStudy Design:\n\nSABRVICAL is a meticulously designed randomized two-arm open-label phase II study to compare QT\u002FRT + SBRT vs QT\u002FRT + Brachytherapy. It will include patients with IB3-IIIC1 CaCu \\>18 years of age with adequate renal function. They will be randomized 1:1 to the experimental arm or the standard arm.\n\nExpected Results and Outlook With this study, we aim to assess that the safety and efficacy of concomitant QT\u002FRT with cisplatin followed by SBRT is not inferior to boost with brachytherapy in patients with CaCu IB3-IIIC1. The potential impact of this study is significant, as it could provide new treatment options for hospitals that do not have brachytherapy or have a prolonged waiting list for this procedure.",[27],"Uterine Cervical Neoplasm","RECRUITING","2025-10-01",{"date":31,"type":32},"2025-10-07","ACTUAL",{"date":34,"type":32},"2024-05-15",{"date":36,"type":21},"2030-12-31",{"name":38,"class":39},"National Institute of Cancerología","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100594881","metabolic-effect-of-exercise-and-diet-in-endometrial-cancer-patients-eligible-for-staging-surgery-100594881","NCT07025213","Metabolic Effect of Exercise and Diet in Endometrial Cancer Patients Eligible for Staging Surgery.","Metabolic Effect of a Physical Activity and Dietary Intervention, and Its Association With Musculoskeletal Changes, in Endometrial Cancer Patients Eligible for Staging Surgery, Compared to Patients Not Receiving the Physical Activity Intervention. A Pilot Study.","Inclusion Criteria:\n\n1. -Ability to understand the nature of the study and provide written informed consent.\n2. -Women aged over 18 and under 65 years.\n3. -Availability to attend exercise sessions.\n4. -Willingness and ability to comply with scheduled visits, the proposed nutritional algorithm, treatment plan, and laboratory tests.\n5. -Histologically confirmed diagnosis of endometrioid-type endometrial cancer by biopsy.\n6. -Normal electrocardiogram (ECG) result.\n7. -No prior oncological treatment.\n8. -Body mass index (BMI) greater than 20 kg\u002Fm².\n9. -Availability of a computed tomography (CT) scan.\n10. -Candidates for staging surgery.\n\nExclusion Criteria:\n\n1. -Patients with advanced clinical stage or stage IVB disease (according to FIGO 2018 criteria).\n2. -Patients with a prior or concurrent malignancy, except non-melanoma skin cancer.\n3. -Patients with uncontrolled systemic arterial hypertension.\n4. -Patients with renal dysfunction (eGFR ≤ 60 mL\u002Fmin\u002F1.73 m²).\n5. -Patients with uncontrolled psychiatric disorders, including claustrophobia.\n6. -Patients with concurrent infections.\n7. -Patients with autoimmune disease.\n8. -Patients with neuromuscular disease.\n9. -Contraindications to physical exercise.\n10. -Vulnerable situations (e.g., homelessness preventing adherence to diet, or incarceration).","65 Years",{"count":50,"type":21},80,[24],"Background:\n\nEndometrial cancer is one of the diseases linked to obesity in women. In Mexico, about 7.6 women out of every 100,000 are diagnosed with this type of cancer, and nearly three-quarters of these women have obesity. Many women with endometrial cancer also have a condition called sarcopenic obesity, where muscle loss happens but might not be easy to identify. Researchers believe that certain molecules in the blood could help identify the health of muscles. Exercise helps muscles stay strong and healthy by affecting these molecules. For women with cancer, staying active can help maintain muscle mass, which is important for better recovery and health outcomes. This project focuses on an exercise program for women with locally advanced endometrial cancer who will be treated surgically at the National Cancer Institute of Mexico (INCan).\n\nWhat We Think Will Happen:\n\nWomen with endometrial cancer who participate in a program combining physical activity and healthy eating will gain more muscle strength and function compared to those who don't exercise. We expect these changes to be connected to healthier levels of certain molecules in the blood, showing less muscle breakdown and less inflammation. We also believe these women will have better control of blood sugar and fats.\n\nOur Main Goal:\n\nTo find out how physical activity and diet affect muscle health and metabolism in women with endometrial cancer, and to compare these changes to women who don't participate in the exercise program.\n\nHow We Will Do It:\n\nWe will measure molecules related to muscle health in the blood. We will also assess muscle size, strength, and how well the muscles work. Then, we will look for connections between these muscle changes and the blood molecules. We want to see if improvements in muscle are linked to better recovery from surgery and better health outcomes. If so, these blood molecules might help doctors monitor muscle health. We hope that the exercise program will help women recover better and improve their quality of life.\n\nHow We Will Analyze the Data:\n\nWe will describe the data we collect and compare the group that exercises to the group that doesn't. We will use statistics to see if the differences are meaningful. We will also analyze the relationship between muscle health and blood markers. Advanced methods will help us identify which molecules and measurements best explain the changes seen. The results will be carefully reviewed using specialized software.\n\nWhat We Hope to Find:\n\nWe aim to show that blood tests can help identify muscle health and how it improves with exercise. This could lead to earlier detection of muscle loss and better management through exercise programs. Ultimately, this work hopes to improve the health and well-being of women facing endometrial cancer.",[54],"Endometrial Cancer",[56,57,58,59,60,61],"excercise","muscle mass and strength","Metabolism changes","inflammation biomarkers","quality of life","surgical complication","2025-06-09",{"date":64,"type":32},"2025-06-17",{"date":66,"type":32},"2025-04-02",{"date":68,"type":21},"2028-12-31",{"name":38,"class":39},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100528111","phase-3-evaluation-of-concomitant-chemo-radiotherapy-with-cisplatine-vs-gemcitabin-in-locally-advanced-cervicouterine-cancer-100528111","NCT06156514","Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer","Evaluation of Concomitant Chemo-radiotherapy With Cisplatin vs Gemcitabine as the First Line of Treatment in Patients With Locally Advanced Cervical Cancer, With Comorbidities and Preserved Renal Function, is a Phase III Clinical Trial.","MICHELE","Inclusion Criteria:\n\n* Singed informed consent.\n* Women with Age ≥ 18 years.\n\n  1. -In women of childbearing age it should be documented: a) negative pregnancy test in serum at the beginning of the study (14 days before the start of QT-RT); b) Accept the use of some method of contraception approved by your attending physician during the study and 12 weeks after the treatment has ended.\n  2. -In postmenopausal women (surgical or natural menopause) at least one of the following parameters must be met for inclusion.\n* Previous bilateral oophorectomy\n* Age ≥ 60 years\n* Age \\\u003C60 years and amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal interval parameters.\n* Diagnosis of CaCu EC IB2 mg\u002Fdl With histological confirmation (epidermoid, adenocarcinoma or adenoescamoso).\n* Patients who are candidates for treatment with concomitant QT \u002F RT.\n* ECOG 0-2.\n* Measurable disease by CT scan and magnetic resonance imaging of the pelvis according to the RECIST criteria v1.1\n* No previous treatment.\n* Creatinine clearance ≥ 60 ml \u002F min calculated by the CKD-EPI formula.\n* Patients with adequate hematological and hepatic functioning, defined by the following parameters:\n\n  1. Hb equal to or greater than 10g \u002Fl. (Transfusion prior to treatment is allowed to reach this level of hemoglobin).\n  2. Leukocytes greater than or equal to 4000 \u002F mm3.\n  3. Platelets equal to or greater than 100,000mm3.\n  4. Total bilirubin ≤1.5 times the upper limit of normal (ULN) and. Transaminases less than 1.5 times the LSN\n* Patients with a prior diagnosis of the following comorbidities:\n\n  * Diabetes mellitus type 2, which has: fasting serum glucose \\\u003C250 mg\u002Fdl.\n  * Systemic arterial hypertension G1 or G2 according to CTCAE v4.03\n  * Child Pugh A liver disease\n  * Cardiovascular diseases such as: Ischemic heart disease undergoing asymptomatic treatment, without clinical data of stable or unstable angina or for acute myocardial infarction.\n  * Compensated heart failure in functional class I of the New York Heart Association.\n  * Systemic Lupus Erythematosus with mild or inactive lupus activity (less than or equal to 4 points according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).\n\nExclusion Criteria:\n\n* Patients with a second neoplasm.\n* Pregnant or lactating patients.\n* Patients with small cell and \u002F or neuroendocrine CaCu.\n* Patients with impaired renal function with a GFR \\\u003Cor equal to 60ml \u002F min calculated by the CKD-EPI formula\n* Patients with a history of active TB (TB)\n* Patients with a history of Human Immunodeficiency Virus (HIV) infection\n* Patients with vesico-vaginal or vesicorectal fistulas at diagnosis\n* Concomitant treatment with another experimental drug. Social, family or geographical conditions that suggest a poor attachment to the study\n\nCriteria Interruption of Treatment (Withdrawal of patients)\n\nA patient will be discontinued from the study under the following circumstances:\n\n* Evidence of disease progression.\n* If treating physician considers that a change of therapy may benefit the patient.\n* If patient withdrew consent\n* Due to unmanageable toxicity By pregnancy or if the patient does not wish to continue using the contraceptive methods indicated by the attending physician",{"count":79,"type":21},140,[81],"PHASE3","The purpose of this phase III clinical trial, is to evaluate the efficacy and safety of concomitant chemo-radiotherapy with Cisplatin vs Gemcitabine as the first line of treatment in patients with locally advanced cervical cancer, with comorbidities and preserved renal function.",[84,85,86],"Locally Advanced Cervical Cancer","Gemcitabine","Chemo-radiotherapy",[88,89,85,90,91],"Locally advanced cervical cancer (LACC)","Concomitant chemo-radiotherapy","Cisplatin","Comorbidities","2025-05-22",{"date":94,"type":32},"2025-05-28",{"date":96,"type":32},"2019-11-06",{"date":98,"type":21},"2029-12-31",{"name":38,"class":39},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100522301","curcumin-supplementation-in-cervical-cancer-100522301","NCT06080841","Curcumin Supplementation in Cervical Cancer","Evaluation of Curcumin Supplementation on p53 Levels and Apoptosis in Tumor Cells From Patients With Locally Advanced Cervical Cancer","Inclusion Criteria:\n\n1. Understanding the nature of the study and giving a written consent report.\n2. Women \\> 18 years old.\n3. ECOG performance status: 0-2.\n4. Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.\n5. Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.\n6. Classified with clinical stage IB3-IVA (FIGO 2018).\n7. Candidates to receive concomitant QT-RT followed by BT.\n8. With disease measurable by any imaging method (CT\u002FMRI\u002FPET-CT) according to RECIST v 1.1 criteria.\n9. Patients without prior treatment based on QT-RT.\n10. Hemoglobin ≥ 10 g\u002FdL.\n11. Leukocytes ≥ 4000\u002Fmm3.\n12. Platelets ≥ 100,000\u002Fmm3.\n13. Adequate liver function.\n\nExclusion Criteria:\n\n1. Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.\n2. Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.\n3. Patients receiving concomitant treatment with an experimental drug.\n4. Patients with vesicovaginal or vesicorectal fistula are diagnosed.\n5. Patients with previous or concomitant malignancy except non-melanoma skin carcinoma.",{"count":108,"type":21},30,[24],"Brief Summary.\n\nThe goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are:\n\n* Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients?\n* At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients?\n* Are all doses safe for supplementation?\n\nParticipants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation:\n\n1. 1 g of curcumin\n2. 1 g of curcumin + piperine\n3. 3 g of curcumin\n4. 3 g of curcumin + piperine\n5. 6 g of curcumin\n6. 6 g of curcumin + piperine",[84],[113,114,115,116,117],"curcumin","locally advanced cervical cancer","p53","apoptosis","chemoradiotherapy",{"date":119,"type":32},"2025-05-25",{"date":121,"type":32},"2023-04-19",{"date":123,"type":21},"2026-03",{"name":38,"class":39},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100293602","phase-2-assessment-of-gemcitabine-as-chemoradiotherapy-in-patients-with-locally-advanced-carcinoma-of-cervix-and-renal-disease-100293602","NCT03101995","Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease","A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease","Inclusion criteria.\n\n1. Patients who give their written consent to participate in the study.\n2. Women, 18-70 years of age, considering the following criteria:\n\n   • In women of childbearing age: i. Negative serum pregnancy test at baseline (14 days prior to the start of QT-RT).\n\n   ii. The patient must accept the use of any contraceptive method approved by the attending physician during the study and 12 weeks after the end of treatment.\n\n   • Postmenopausal women must meet at least one of the following parameters for eligibility: i. Prior bilateral oophorectomy ii. Age ≥ 60 years iii. Age \\\u003C 60 years, with amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal parameters.\n3. Diagnosed with CC IB2-IVA, with or without retroperitoneal lymph nodes (para-aortic), smaller than 2 cm.\n4. With histologic confirmation of squamous carcinoma, adenosquamous carcinoma, adenocarcinoma or glassy cells carcinoma.\n5. Without previous treatment and medically able to receive gemcitabine.\n6. Disease measurable by CT and\u002For MRI according to RECIST (v1.1) criteria.\n7. Functional status of 0-3 according to WHO criteria.\n8. Renal dysfunction defined by glomerular filtration (GF) \\\u003C60 ml\u002Fmin\u002F1.73m2 calculated by the CKD-EPI formula.\n9. Normal hematologic and liver function, as defined by the following parameters:\n\n   * Hemoglobin \\> 10g\u002FL. (Transfusion prior to the treatment is allowed to reach this level of hemoglobin).\n   * Leucocytes \\> 4000\u002Fmm3.\n   * Platelets \\> 100,000\u002Fmm3.\n   * Total Bilirubin ≤1.5 times the upper normal limit (UNL).\n   * Transaminases \\\u003C 1.5 times the UNL.\n10. Normal PA chest radiograph.\n\nExclusion criteria.\n\n1. Patients with prior or concomitant malignancy, except non-melanoma skin carcinoma.\n2. Patients with diabetes and\u002For hypertension with retinopathy or albuminuria \\>300.\n3. Patients with evidence of active TB infection.\n4. Patients infected with Human Immunodeficiency Virus (HIV).\n5. Patients with a history of Systemic Lupus Erythematosus and other rheumatologic diseases that cause kidney damage.\n6. Patients with vesicovaginal or vesicorectal fistula at the time of diagnosis.\n7. Patients with uncontrolled intercurrent diseases including active infections that contraindicate QT, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, decompensated diabetes, difficult control hypertension and psychiatric illness.\n8. Concomitant treatment with other experimental drugs.\n9. Social, family or geographical conditions that suggest a poor adherence to the study.\n\nStudy discontinuation criteria.\n\n1. Evidence of disease progression, if the researcher considers that the patient would benefit more with other therapy.\n2. At the request of the patient.\n3. By unacceptable toxicity.\n4. Pregnancy.\n\nViolation of starting criteria. Criteria must be followed punctually. If a patient were inappropriately included, she must be discontinued from the study.","70 Years",{"count":134,"type":21},18,[136],"PHASE2","From the global burden of Cervical Cancer (CC), 85% occurs in developing countries, representing 12% of cancer in women. In Mexico CC ranks second in incidence and mortality among women. The National Institute of Cancer in Mexico (lNCAN) receives annually about 500 patients with CC, 80% of which are diagnosed with locally advanced disease. Furthermore, 10 to 20% of these present kidney deterioration. The main reason for kidney disease is ureteral obstruction, other causes include age and comorbidities, such as diabetes and hypertension. The standard treatment for locally advanced disease consists in concomitant chemo-radiotherapy based on cisplatin (QT-RT), followed by brachytherapy, with an absolute benefit of 10%. However, the use of cisplatin in patients with renal disease may be questionable, considering it is a nephrotoxic treatment. Given that renal dysfunction limits the standard treatment efficiency because of the widely known nephrotoxicity of cisplatin, in most Cancer Centers of our country, patients with renal dysfunction receive only radiation therapy, even though it has proven less effective than concomitant QT-RT, limiting disease-free and overall survival of these patients. Venook et al. used gemcitabine as a radiosensitizer in patients with cancer and renal dysfunction. Our group, has observed encouraging results using gemcitabine as an alternative to cisplatin in concomitant treatment with radiotherapy, in CC patients with renal insufficiency. 89% of patients had complete response and improvement in renal function, with an enhanced creatinine clearance after treatment. Therefore, it is necessary to explore the safety of gemcitabine as an alternative treatment for CC patients with locally advanced disease and renal deterioration. We propose this clinical trial to assess the safety of treatment with gemcitabine and specifically on renal function in patients with renal deterioration. It is important to take into consideration that CC in advanced stages produces pain, transvaginal fetid discharge and general discomfort. It also causes side effects secondary to renal failure such as nausea, vomiting, fatigue, anemia, among others. These effects have a significant impact on the quality of life of these patients. Cancer treatment and its side effects, besides the implications of a nephrostomy catheter or ileostomy bag, determine the deterioration in the quality of life of the patient, during and sometimes after treatment. Thus it is of utmost importance to evaluate the factors that could help improve the quality of life of patients and explore the factors that deteriorate it. This clinical trial aims to generate scientific evidence to help make the best decisions concerning the treatment of patients with cervical cancer and renal impairment, and the impact on their quality of life.",[139],"Cervical Cancer",[141,142,143,85],"Treatment","Locally advanced cervical cancer","Renal failure",{"date":94,"type":32},{"date":146,"type":32},"2018-01-16",{"date":148,"type":21},"2025-11-01",{"name":38,"class":39},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":40},"100531921","molecular-classification-in-mexican-patients-with-endometrial-cancer-and-its-impact-on-prognosis-100531921","NCT06206083","Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis","Criteria: Inclusion Criteria:\n\n* Clinical diagnosis of endometrioid-type endometrial cancer with samples available\n* That the patients have undergone surgery at INCan.\n\nExclusion Criteria:\n\n* Samples with CEE of non-endometroid type.\n* Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ\n* History of malignancy \\\u003C 5 years prior with no evidence of disease (i.e., remission).",{"count":157,"type":21},64,"OBSERVATIONAL","Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.",[54],[162,163],"Endometrial cancer","Prognostic factors","2024-02-27",{"date":166,"type":32},"2024-02-28",{"date":168,"type":21},"2024-03-01",{"date":170,"type":21},"2027-02-01",{"name":38,"class":39},""]